An EU-OPENSCREEN screening site will take the robust, miniaturised assay together with established orthogonal and counter screens through the high throughput screening (HTS) process, followed by confirmatory (dose response) and counter screening (identical assay without the target or with non-functional target), until a final list of confirmed hit compounds is established.

This process includes the following services:

  • HTS (of the entire EU-OPENSCREEN chemical collection)
  • In silico profiling, including basic chemoinformatic analysis and identification of frequent hitters and other potential false positives
  • Hit selection
  • Confirmatory screening, including orthogonal assay and IC/EC50 determination
  • Basic counter screening
  • Basic SAR based on screening data
  • QC of confirmed hits for a biochemical screen, the hit confirmation process includes testing for activity in a cell-based model.
  • Fragment based library screening
  • Virtual screening

For more information you can watch our introductory video on high-throughput-screening (HTS) here.


Screening partner sites


Palacký University Olomouc - Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine (IMTM)

Dr. Marian Hajduch, Dr. Petr Dzubak

Information PDF


Institute of Molecular Genetics AS CR, v. v. i. (IMG)

Dr. Petr Bartůněk

Information PDF 


University of Helsinki, Faculty of Pharmacy - Division of Pharmaceutical Biosciences

Prof. Arto Urtti

Information PDF


Institute for Molecular Medicine Finland (FIMM) - High Throughput Biomedicine (HTB) unit

Prof. Päivi Tammela

Information PDF 


University of Turku, BioCityTurku (BCT)

Prof Michael Courtney


Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP)/MDC Berlin - Chemical Biology – Screening Unit

Dr. Jens Peter von Kries

Information PDF


Helmholtz-Zentrum für Infektionsforschung GmbH (HZI) - Department of Chemical Biology (CBIO)

Prof. Mark Brönstrup

Information PDF


Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) – Drug Discovery - Screening Port

Dr. Philip Gribbon

Information PDF


University of Bergen, Department of Biomedicine - Faculty of Medicine and Dentistry

Prof. Aurora Martinez

Information PDF


University of Oslo - Faculty of Medicine / Biotechnology Centre of Oslo (BiO) and Centre for Molecular Medicine (NCMM)

Dr. Johannes Landskron

Information PDF


Arctic University of Norway, Faculty of Biosciences, Economics and Fisheries

Prof. Jeanette H. Andersen

Information PDF


SINTEF Materials and Chemistry

Dr. ing. Geir Klinkenberg

Information PDF


Polish Academy of Sciences - Institute of Medical Biology, Screening laboratory for anti-viral and anti-bacterial compounds (IMB PAS)

Prof. Dr. Zbigniew J. Leśnikowski

Information PDF


Polish Academy of Science - Institute of Bioorganic Chemistry (IBCH)

Dr. Radosław Pilarski, Dr. Jacek Kolanowski

Information PDF


Institute of Molecular and Cell Biology - Innovation and Health Research Institute of Porto University (i3S-LA)

Antonio Pombinho


University of Coimbra - Centre for Neuroscience and Cell Biology (CNC-UC)

Miguel Mano


FUNDACION MEDINA - Screening and target validation, Microbiology and Chemistry

Dr. Olga Genilloud

Information PDF


Prince Felipe Research Center (CIPF) - Advanced Therapies Program, Screening Platform

Dr. María J. Vicent,

Information PDF


University of Santiago de Compostela - BioFarma Research Group

Prof. Mabel Loza

Information PDF


Karolinska Institutet - Department Medical Biochemistry and Biophysics (CBCS-KI)

Anna-Lena Gustavsson


Umeå University - Chemical Biology Centre (CBCS-UmU)

Erik Chorell